ALIPAY+
9.1.2023 07:16:19 CET | Business Wire | Press release
Alipay+, a provider of global cross-border digital payment and marketing solutions, is striving to provide cash-free and mobile-friendly travel experiences for Asian tourists in the Chinese mainland, as it seeks to partner with more merchants and enable greater QR code connectivity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230107005009/en/
AlipayHK users are now able to pay for metro rides in Shenzhen using the app the same way they do at home, as China begins to optimize regulations on travel between mainland and Hong Kong. (Photo: Business Wire)
Starting from January 8, AlipayHK users can pay for metro rides in Shenzhen using their local app to enhance a seamless travel experience for Hong Kong visitors in the mainland. The service is enabled through joint efforts between Alipay+ and the city’s subway operator, following a similar payment system integration with bus operators in major cities across Guangdong province.
Venetia Lee, General Manager of Ant Group Greater China International Business, said, “As a pioneer in the field of digital life, we hope to play a bigger role in building digital infrastructure to enhance connectivity in the Greater Bay Area, and contribute to the better development of the region.”
The expanded acceptance of AlipayHK comes as China begins to optimize regulations on travel between mainland and Hong Kong, lifting quarantine requirements that were in place for almost three years.
“As the demand for travels between mainland and Hong Kong remains strong and cross-bound activities begin to normalize, we expect to witness the wide adoption of AlipayHK on the Chinese mainland, where Alipay+ solutions have already been adopted by millions of merchants that are ready for the return of international travelers,” said Lee.
Powered by Alipay+ solutions, AlipayHK, one of the most popular e-wallets in Hong Kong, is now widely accepted in the mainland by retailers, convenient stores, supermarkets, restaurants, cafes, bubble tea shops, hotels and other tourist spots in the mainland, where users can scan the same local merchant’s QR code for payment or present their in-app QR code to be scanned for payment.
Cash Free Travel to Users of Alipay+ Mobile Payment Partners
The connectivity with merchants across China is not limited to AlipayHK. Last November, Alipay+ announced on the sideline of the Singapore Fintech Festival that its mobile payment partners including South Korea’s Kakao Pay and Malaysia’s Touch 'n Go eWallet would soon be accepted in mainland, in a drive to facilitate payments from international visitors ahead of the Hangzhou Asian Games.
After a trial run in Yiwu, Zhejiang province, users of Kakao Pay and Touch 'n Go eWallet are expected to pay in a seamless way with their respective apps while getting around in Hangzhou and its neighboring cities where the Hangzhou Asian Games will take place, in addition to other major Chinese cities including Beijing, Shanghai and Shenzhen.
Alipay+ offers unified global mobile payment and marketing solutions that connect merchants with multiple e-wallets and payment methods. Consumers can conveniently use their preferred local payment methods while transacting seamlessly in a different market and be able to enjoy marketing offers by the merchants through Alipay+.
Alipay+ Global Footprint
Globally, over the past year Alipay+’s merchant coverage has more than doubled since last year to over 2.5 million, which includes regional and global digital entertainment providers, lifestyle services, e-commerce platforms and a wide range of brick-and-mortar businesses that cover major airports, shopping centers, duty free shops, convenience stores, cafes, restaurants and tourism facilities.
Businesses across Japan, South Korea, Singapore, Malaysia and other Southeast Asian markets are embracing Alipay+ to connect with over 15 digital payment methods through one-time integration, and better engage with over 1 billion consumers.
Alipay+’s merchant coverage includes over 1,000 online platforms, more than 10 major airports, over 90,000 convenience stores, over 360,000 restaurants, nearly 200,000 taxis and major hotel brands, department stores, duty-free shops and tourist facilities in Asia and Europe.
About Alipay+
Alipay+ offers unified global mobile payment and marketing solutions that connect merchants with multiple e-wallets and payment methods from different countries and regions by collaborating with global partners. Consumers can conveniently use their preferred local payment methods while transacting seamlessly in a different market and be able to enjoy marketing offers by the merchants through Alipay+. Alipay+ is developed by Ant Group, the owner and operator of Alipay, one of the world’s leading digital open platforms.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230107005009/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom